Milestone Pharmaceuticals Inc
MIST1.825USD
+0.065+3.69%
交易中 （美东）报价延迟15分钟
155.43M总市值
亏损市盈率 TTM
关于 Milestone Pharmaceuticals Inc 公司
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc简介
公司代码MIST
公司名称Milestone Pharmaceuticals Inc
上市日期May 09, 2019
CEOOliveto (Joseph)
员工数量33
证券类型Ordinary Share
年结日May 09
公司地址420-1111 boul. Dr.-Frederik-Philips
城市MONTREAL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编H4M 2X6
电话15143360444
网址https://www.milestonepharma.com
公司代码MIST
上市日期May 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Jeffrey Nelson
Mr. Jeffrey Nelson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+7855.00%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+7855.00%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+50000.00%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
其他
68.16%
持股股东
持股股东
占比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Propel Bio Management, LLC
6.02%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
其他
68.16%
股东类型
持股股东
占比
Investment Advisor
16.52%
Hedge Fund
14.43%
Venture Capital
6.24%
Research Firm
5.04%
Individual Investor
3.97%
Investment Advisor/Hedge Fund
3.95%
Private Equity
3.78%
Family Office
1.17%
Bank and Trust
0.02%
其他
44.87%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
119
42.67M
50.10%
+14.57M
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Simplify Asset Management Inc
7.96M
9.34%
+5.18M
+186.09%
Sep 30, 2025
Adage Capital Management, L.P.
6.98M
8.19%
+6.98M
--
Sep 30, 2025
Propel Bio Management, LLC
5.12M
6.02%
+4.27M
+502.93%
Jul 11, 2025
Trails Edge Capital Partners LP
3.83M
4.5%
-1.50M
-28.13%
Sep 30, 2025
OrbiMed Advisors, LLC
3.22M
3.78%
+3.22M
--
Sep 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
Morgan Stanley & Co. LLC
2.63M
3.09%
+1.81M
+221.87%
Sep 30, 2025
RTW Investments L.P.
2.51M
2.94%
--
--
Sep 30, 2025
Pathstone
1.00M
1.17%
+1.00M
--
Sep 30, 2025
Two Sigma Investments, LP
900.59K
1.06%
+900.59K
--
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
占比8.04%
SPDR S&P International Small Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
